Skip to content
Tuesday 18 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,722.78
+0.02%
DAX
26,266.69
-0.27%
CAC 40
8,548.16
-0.37%
STOXX 50
6,499.38
-0.48%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Thursday 11 February 2021 11:49 am

Astrazeneca confirms it will roll out new vaccine for Covid mutations in autumn

By: Poppy Wood

Add as a preferred source on Google
autumn social distancing
Social distancing measures could stay in place to curb the spread of new variants

Astrazeneca is on course to launch a new vaccine that is effective against emerging Covid variants by the autumn, the company has said.

The Anglo-Swedish firm said clinical trials for the “next generation” of Covid vaccine would commence in the spring, with mass production earmarked for six to nine months’ time.

Speaking as he unveiled Astrazeneca’s annual results, chief executive Pascal Soriot said there should be a drop in hospital admissions “very soon” as a consequence of the UK’s vaccine rollout.

Astrazeneca this morning revealed sales at the biotech firm jumped 10 per cent to nearly $26bn in 2020, in a year that made the at pharmaceutical company a household name.

The UK has ordered 100m doses of its Covid vaccine made in collaboration with Oxford University. The drug has proved instrumental in Britain’s largest ever immunisation programme, which has seen more than 13m people receive their first dose of the jab so far.

The company said it will deliver 100m doses of its current vaccine around the world this month alone, doubling to 200m per month by April.

“We’re going to save thousands of lives and that’s why we come to work every day as individuals,” said Soriot.

“Is it perfect? No it’s not perfect, but it’s great. Who else is making 100m doses in February?” he added.

Soriot’s comments follow new data published over the weekend that showed the Astrazeneca jab was less effective against a fast-spreading South African variant of the virus.

But the company was dealt a major boost yesterday as the World Health Organization recommended use of its vaccine in all age groups without limitations, adding that it would still prevent severe illness from the South African variant.

Read more

Astrazeneca explores $400bn megadeal with US rival 

AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.

The two-dose shot has been hailed as a “vaccine for the world” because it is easier to store than some other jabs, while Astrazeneca has pledged not to make a profit on it during the pandemic.

Emerging variants

Details of the timeline for Astrazeneca’s new Covid vaccine comes after the Prime Minister said yesterday that the most vulnerable members of the population will likely need booster jabs especially suited to Covid mutations “every year”.

“I think we need to be getting ready for a world in which we do have booster jabs against new variants in the autumn and maybe beyond. We should start to think about it as a flu jab — as something elderly and vulnerable people make sure they have every year,” he told a Downing Street press conference.

The director of the UK’s genetic surveillance programme said this morning that the more virulent variant of coronavirus first identified in Kent will become the world’s dominant strain of the virus.

The Kent variant is now the most common form of the virus in the UK, after it was first detected in September. It has been cited as the reason for the introduction of new lockdown rules across the UK in January after causing a massive surge in coronavirus cases.

“It’s going to sweep the world, in all probability”, said Professor Sharon Peacock from the Covid-19 Genomics UK (Cog-UK) Consortium.

Peacock told the BBC her work sequencing variants of the virus could be required for at least a further 10 years.

“Once we get on top of it [Covid-19] or it mutates itself out of being virulent — causing disease — then we can stop worrying about it,”she said. 

“But I think, looking in the future, we’re going to be doing this for years. We’re still going to be doing this 10 years down the line, in my view.”

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business
  • Tech

Related Topics

  • AstraZeneca
  • Coronavirus
  • Re-lockdown
  • Vaccine

Trending Articles

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • US bond market jitters spark UK economy recession warning

  • Aldi boss wades into supermarket ‘price-gouging’ row

  • Monzo chair makes early exit after boardroom rift

  • New Premier League rules could see £11bn invested into new stadiums

More from Morning Wire

  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Astrazeneca and Jaguar Land Rover given power to endorse talented migrants for visas

    Politics
    Jonathan Reynolds addressing the SMMT's annual International Automotive Summit (image courtesy of SMMT)
  • As it happened: UK stocks cool after Astrazeneca drags; Trump and Iran clash over peace talks

    FTSE 100 Live
    Donald Trump speaking at a desk, gesturing with hands, wearing a dark suit and red tie.
  • Sweeping job cuts at GSK to fund £400m Cambridge campus

    Pharma
    Modern GSK Cambridge campus buildings with sky bridge, green spaces, and people walking and cycling.
  • ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise

    Business Wire
  • As it happened: Stocks fall as oil creeps up; Trump to ‘finish job’ in Iran

    Markets
    Donald Trump speaking at the PAAP office conference, addressing key political issues and strategies in a formal setting.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook